National Institutes of Health All of Us Research Program

National Institutes of Health All of Us Research Program
Name	All of Us Research Program
Formation	2018
Headquarters	Bethesda, Maryland
Parent organization	National Institutes of Health

National Institutes of Health All of Us Research Program

The All of Us Research Program is a large-scale biomedical research initiative administered by the National Institutes of Health in Bethesda, Maryland that aims to gather health data from one million or more participants to accelerate precision medicine and population health research. Designed as a longitudinal cohort study, the program seeks to create a diverse research resource by combining electronic health records, biospecimens, wearable device data, and participant-reported information while engaging with stakeholders including academic institutions, private partners, and community organizations.

Overview

The program was launched by the National Institutes of Health with the goal of enrolling a million participants across the United States of America to generate a research database linking genomic, environmental, and clinical data from diverse populations. It emphasizes inclusion of underrepresented groups in biomedical research, collaborating with entities such as the Centers for Disease Control and Prevention, Food and Drug Administration, Massachusetts General Hospital, Kaiser Permanente, and community-based organizations to ensure broad representation. The resource supports investigators at institutions like Harvard University, Stanford University, Johns Hopkins University, and University of California, San Francisco through data access governed by policy frameworks aligned with federal statutes including the Health Insurance Portability and Accountability Act.

History and Development

Origins trace to strategic initiatives by the National Institutes of Health under directors and advisory councils responding to calls for cohort studies similar in scale to the Framingham Heart Study and international efforts such as the UK Biobank and the Icelandic Health Sector Database. Announced during the administration of Barack Obama and developed amid input from advisory committees, the program built infrastructure through contracts with consortia led by organizations including Scripps Research, Vanderbilt University Medical Center, and technology partners like Google and Apple. Recruitment phases unfolded alongside policy developments involving the Office for Human Research Protections, the Common Rule, and discussions in the United States Congress about federal research priorities. The program’s development intersected with public debates during events such as the COVID-19 pandemic and initiatives promoted by the Precision Medicine Initiative.

Objectives and Research Scope

Primary objectives include enabling research on genetic determinants of disease, pharmacogenomics, environmental exposures, and social determinants of health by providing de-identified datasets to investigators affiliated with institutions such as Columbia University, University of Michigan, University of Pennsylvania, and Yale University. The scope spans chronic conditions studied in cohorts like the Nurses' Health Study and outcomes examined in trials such as the Systolic Blood Pressure Intervention Trial, supporting investigations into cancer research linked to centers like the National Cancer Institute, cardiovascular disease research associated with the National Heart, Lung, and Blood Institute, and neuroscience projects related to the National Institute of Mental Health. The program’s data enable cross-disciplinary projects involving teams from entities including Mayo Clinic, Cleveland Clinic, Fred Hutchinson Cancer Center, and pharmaceutical partners such as Pfizer and Johnson & Johnson.

Participant Recruitment and Diversity Initiatives

Recruitment strategies prioritized enrollment of populations historically underrepresented in biomedical studies, engaging community partners like the NAACP, Hispanic Federation, and tribal organizations including the Cherokee Nation and the Navajo Nation. Outreach efforts included partnerships with health systems like Mount Sinai Health System, University of Texas Southwestern Medical Center, and community clinics affiliated with Planned Parenthood and federally qualified health centers. Initiatives to increase diversity involved collaborations with advocacy groups such as the American Cancer Society and the Alzheimer's Association, academic programs at institutions like Howard University and Morehouse School of Medicine, and public events tied to observances recognized by the National Institutes of Health.

Data Collection, Privacy, and Security

Data collection encompasses electronic health records from vendors like Epic Systems Corporation and Cerner Corporation, genomic sequencing performed in labs associated with Broad Institute and Illumina, wearable-device data from companies including Fitbit and Apple Inc., and survey instruments used by researchers at University of Washington and University of California, Los Angeles. Privacy protections rely on de-identification protocols shaped by the Health Insurance Portability and Accountability Act and guidance from the Office of the National Coordinator for Health Information Technology, with technical safeguards implemented in collaboration with cloud providers such as Amazon Web Services and Google Cloud Platform. Governance mechanisms include Certificates of Confidentiality and data access committees modeled on standards used by the National Human Genome Research Institute.

Governance, Funding, and Partnerships

Governance involves oversight from advisory boards including experts from National Academy of Medicine and coordination with institutes like the National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases. Funding streams derive primarily from appropriations to the National Institutes of Health with supplemental cooperative agreements and contracts awarded through competitive procurement to consortia led by entities such as Scripps Research Translational Institute and Vanderbilt University Medical Center. Public–private partnerships have included collaborations with academic centers, technology firms, pharmaceutical corporations, and non-profit organizations like the Bill & Melinda Gates Foundation and Robert Wood Johnson Foundation.

Impact, Findings, and Criticism

The program has produced datasets enabling studies published by researchers at institutions including Harvard Medical School, University of California, Berkeley, and University of Oxford, with early analyses informing genomic associations and population health models used by groups such as the Global Alliance for Genomics and Health. Criticisms have arisen from scholars and advocates at organizations such as the Electronic Frontier Foundation and academic commentators in journals like Nature and Science regarding consent models, data access policies, and potential commercialization through partnerships with companies like Thermo Fisher Scientific and Regeneron. Debates also reference precedent controversies involving the Henrietta Lacks case and ethical frameworks developed after the Tuskegee syphilis study. Continued evaluation by bodies including the National Academies of Sciences, Engineering, and Medicine informs policy refinement and programmatic adjustments.

Category:Biomedical research programs